Literature DB >> 6630325

Effect of the calcium antagonist nimodipine on the delayed hypoperfusion following incomplete ischemia in the rat.

M L Smith, E Kågström, I Rosén, B K Siesjö.   

Abstract

Regional cerebral blood flow (CBF) was measured autoradiographically in the recovery period following 15 min of forebrain ischemia in rats pretreated with either nimodipine (0.1 mg kg-1) or vehicle. The results showed that although nimodipine increased postischemic CBF, the flow enhancement was regionally heterogeneous, sometimes resulting in zones of gross hypoperfusion and overt hyperemia within the same structures. This patchy improvement of delayed postischemic hypoperfusion was not accompanied by recovery of sensory evoked responses, and return of EEG activity was not enhanced.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630325     DOI: 10.1038/jcbfm.1983.83

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  10 in total

1.  Calcium and long-term transmission damage following anoxia in dentate gyrus and CA1 regions of the rat hippocampal slice.

Authors:  I S Kass; P Lipton
Journal:  J Physiol       Date:  1986-09       Impact factor: 5.182

2.  Compared effects of calcium entry blockers on calcium-induced tension in rat isolated cerebral and peripheral resistance vessels.

Authors:  G Julou-Schaeffer; J L Freslon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

3.  Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat.

Authors:  P A Calle; M G Bogaert; L De Ridder; W A Buylaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

Review 4.  Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection.

Authors:  R Hall; J Murdoch
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

Review 5.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Experimental intracerebral haemorrhage: the effect of nimodipine pretreatment.

Authors:  E J Sinar; A D Mendelow; D I Graham; G M Teasdale
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

7.  Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia.

Authors:  Shintaro Gomi; Mark G Burnett; Andrea Karp; Joel H Greenberg
Journal:  Exp Brain Res       Date:  2004-01-30       Impact factor: 1.972

8.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

9.  Inability of flunarizine, lidoflazine or magnesium to counteract delayed hypoperfusion after forebrain ischaemia in the rat.

Authors:  B Grøgaard; B Gerdin; K E Arfors
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

10.  Nimodipine has no effect on the cerebral circulation in conscious pigs, despite an increase in cardiac output.

Authors:  W J van der Giessen; D J Duncker; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.